Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp lessened its holdings in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 98.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,897 shares of the company's stock after selling 595,949 shares during the quarter. Boston Trust Walden Corp's holdings in Henry Schein were worth $825,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Baystate Wealth Management LLC increased its holdings in Henry Schein by 2,500.0% in the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company's stock worth $39,000 after buying an additional 500 shares during the period. McGlone Suttner Wealth Management Inc. acquired a new position in Henry Schein in the 4th quarter worth approximately $39,000. Neo Ivy Capital Management acquired a new position in Henry Schein in the 3rd quarter worth approximately $46,000. Covestor Ltd boosted its position in Henry Schein by 88.4% in the 1st quarter. Covestor Ltd now owns 861 shares of the company's stock worth $75,000 after purchasing an additional 404 shares in the last quarter. Finally, RVW Wealth LLC purchased a new stake in Henry Schein in the 3rd quarter worth approximately $104,000. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Trading Down 0.5 %

Shares of NASDAQ:HSIC traded down $0.37 during midday trading on Friday, reaching $72.52. 581,611 shares of the company's stock were exchanged, compared to its average volume of 1,046,018. The firm's 50 day simple moving average is $75.14 and its two-hundred day simple moving average is $72.62. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. The stock has a market cap of $9.32 billion, a price-to-earnings ratio of 23.02, a P/E/G ratio of 1.80 and a beta of 0.87. Henry Schein, Inc. has a fifty-two week low of $60.01 and a fifty-two week high of $85.75.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The firm had revenue of $3.02 billion for the quarter, compared to analysts' expectations of $3 billion. During the same quarter last year, the business earned $1.21 earnings per share. The business's revenue was down 10.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on HSIC shares. Evercore ISI upped their price objective on Henry Schein from $79.00 to $83.00 and gave the stock an "in-line" rating in a research report on Wednesday, February 28th. Piper Sandler raised their target price on Henry Schein from $78.00 to $86.00 and gave the stock an "overweight" rating in a research note on Monday, February 26th. TheStreet raised Henry Schein from a "c+" rating to a "b-" rating in a research note on Monday, February 26th. Jefferies Financial Group raised their target price on Henry Schein from $74.00 to $81.00 and gave the stock a "hold" rating in a research note on Wednesday, March 6th. Finally, SVB Leerink initiated coverage on Henry Schein in a research note on Monday, February 26th. They issued a "market perform" rating and a $78.00 target price for the company. One analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $81.09.

Insider Activity at Henry Schein

In related news, CEO Bradford C. Connett sold 6,430 shares of the firm's stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the transaction, the chief executive officer now owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now owns 209,562 shares of the company's stock, valued at approximately $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.